H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $39 price target on Dova Pharmaceuticals after the company reported Q2 earnings results that missed on EPS and revenue. However, the analyst believes there is a "significant market" for Dova's Doptelet in cITP, which was just approved in the U.S. The analyst added that the first three weeks of its launch looked "promising." Pantginis is looking for "commercial partnerships for Doptelet in validated clinical indications in ex-U.S. territories" as an upcoming catalyst for the stock in 2019 and 2020.